Wyeth Around the World
In 2008, Wyeth spent approximately $3.3 billion on research and
development, with an emphasis on pharmaceutical, vaccine and biopharmaceutical
approaches to treating and preventing disease. Moving forward, the focus of our
discovery efforts will be to address high unmet needs in six core therapeutic
areas: oncology, inflammation, neurosciences (including Alzheimer's disease),
vaccines, metabolic disorders and musculoskeletal. Wyeth's R&D pipeline
includes novel candidate medicines across our three platforms - small
molecules, vaccines, and biopharmaceuticals. Many of these candidate medicines
have the potential to be first-in-class, best-in-class, and/or
first-in-therapy.
Wyeth in Canada
Wyeth Canada's research and development activities in Montreal include a
state-of-the-art facility comprised of a Clinical Research and Development
centre, a Clinical Supply division, a Chemical Development division and various
support groups.
Wyeth researchers in Canada are conducting a number of clinical and
post-marketing studies in a range of therapeutic areas including women's
health, infectious disease, neuroscience, transplantation, immunology and
vaccines and oncology.
Wyeth Canada-Investing in Canadian Research
-
In 2008, Wyeth Canada invested $66.5 million (CDN) in research and
development in Canada
-
In 2008, Wyeth Canada created two Clinical Research Chairs in Transplantation
at the University of Toronto and the University of Western Ontario. Chairs in
Vaccines, Women's Health, Transplantation, and Oncology are all co-funded by
Wyeth Canada, the Canadian Institutes for Health Research (CIHR) and the
recipient's university. Each Chair is worth a total of $1.1 million over
five years.
-
In partnership with the CIHR, Wyeth Canada also funds six annual, two year
research fellowships. In 2008, these were awarded in the areas of oncology (1),
transplantation (1), women's health (1), neuroscience (1) and infectious
disease (2).
-
Continuing our strong support of excellence in research, Wyeth, along with the
Canadian Institute of Health Research (CIHR) and Rx&D, recently announced
another investment of $1.1 million over five years to fund a Clinical
Research Chair in Oncology. Dr. Michael Jewett, from the Princess
Margaret Hospital and University of Toronto is the recipient.
-
Wyeth Canada's Care Until Cure Research Program is the largest
grant of its kind managed by the Canadian Hemophilia Society. The award
provides annual grants to Canadian investigators to research bleeding
disorders.
-
Wyeth Canada's innovative Partnering for Protection grant
program supports activities and programs aimed at creating new approaches to
understand and/ or improve routine pneumococcal childhood immunization coverage
rates in Canada.
Français
